- Report
- June 2023
- 175 Pages
Global
From €5730EUR$5,950USD£4,928GBP
- Report
- March 2024
- 175 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- February 2024
- 200 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- February 2024
- 175 Pages
Global
From €3852EUR$4,000USD£3,313GBP
- Report
- February 2024
- 175 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- February 2024
- 175 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- February 2024
- 175 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- February 2024
- 175 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- January 2024
- 175 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- January 2024
- 175 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- January 2024
- 200 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- February 2024
- 126 Pages
Global
From €2879EUR$2,990USD£2,476GBP
- Report
- November 2023
- 145 Pages
Global
From €2407EUR$2,499USD£2,070GBP
- Report
- May 2024
- 220 Pages
Global
From €4767EUR$4,950USD£4,100GBP
- Report
- May 2024
- 292 Pages
Global
From €5393EUR$5,600USD£4,638GBP
- Report
- May 2024
- 453 Pages
Global
From €5585EUR$5,800USD£4,804GBP
- Report
- May 2024
- 150 Pages
Global
From €5393EUR$5,600USD£4,638GBP
- Report
- March 2024
- 135 Pages
Global
From €3755EUR$3,899USD£3,229GBP
- Report
- June 2023
- 71 Pages
Global
From €4767EUR$4,950USD£4,100GBP
- Drug Pipelines
- July 2023
- 30 Pages
Global
From €3130EUR$3,250USD£2,692GBP
The Orphan Drug market is a subset of the Pharmaceutical industry that focuses on the development and commercialization of drugs for rare diseases. These drugs are typically developed to treat diseases that affect fewer than 200,000 people in the United States. The Orphan Drug Act of 1983 was passed to incentivize the development of these drugs by providing tax credits, grants, and other incentives to companies that develop them.
The Orphan Drug market has grown significantly in recent years, with more companies entering the market and more drugs being developed. This growth has been driven by advances in medical technology, increased public awareness of rare diseases, and the availability of government incentives.
Some companies in the Orphan Drug market include AbbVie, Amgen, Biogen, Gilead Sciences, and Novartis. Show Less Read more